This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wininger, D. A.
Right arrow Articles by Fass, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wininger, D. A.
Right arrow Articles by Fass, R. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2002, p. 594-597, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.594-597.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Impact of Trimethoprim-Sulfamethoxazole Prophylaxis on Etiology and Susceptibilities of Pathogens Causing Human Immunodeficiency Virus-Associated Bacteremia

David A. Wininger* and Robert J. Fass

Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio

Received 25 April 2001/ Returned for modification 19 August 2001/ Accepted 16 November 2001

The impact of chronic prophylactic administration of trimethoprim-sulfamethoxazole (SXT) on the ecology and the antimicrobial susceptibilities of bloodstream pathogens in human immunodeficiency virus (HIV)-infected patients was studied using a retrospective chart review. Eighty-nine patients with advanced HIV infection developed 124 episodes of bacteremia with 156 pathogenic isolates. Staphylococcus aureus and Enterobacteriaceae tended to be less common among patients receiving SXT. Isolates from patients receiving SXT were likelier (75%) to be resistant to 20 µg of SXT/ml than those from patients not receiving SXT (33%) (P < 0.001).

* Corresponding author. Mailing address: N1135 Doan Hall, 410 West 10th Ave., Columbus, OH 43210. Phone: (614) 293-8732. Fax: (614) 293-4556. E-mail: wininger-1{at}medctr.osu.edu.

Antimicrobial Agents and Chemotherapy, February 2002, p. 594-597, Vol. 46, No. 2
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.2.594-597.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»